Literature DB >> 14562852

HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors.

Mark A Wainberg1.   

Abstract

Nevirapine and other members of the non-nucleoside reverse transcriptase inhibitor (NNRTI) family of anti-HIV-1 drugs are essential components of antiretroviral treatment regimens. Unfortunately, drug resistance has become an important issue with respect to all therapeutic targets in HIV-1. This paper summarizes current knowledge about the mutations in the reverse transcriptase gene of HIV-1 that are responsible for drug resistance and the mechanisms whereby drug resistance develops.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14562852     DOI： 10.1097/00126334-200309011-00002

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


  19 in total

1.  Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.

Authors:  D González de Requena; S Bonora; S Garazzino; M Sciandra; A D'Avolio; R Raiteri; R Marrone; M Boffito; F G De Rosa; A Sinicco; G Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  2D and 3D QSAR studies of diarylpyrimidine HIV-1 reverse transcriptase inhibitors.

Authors:  Joseph Rebehmed; Florent Barbault; Cátia Teixeira; François Maurel
Journal:  J Comput Aided Mol Des       Date:  2008-05-28       Impact factor: 3.686

3.  Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Maureen Oliveira; Daniel Rajotte; Richard Bethell; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Wei Huang; Maureen Oliveira; Yingshan Han; Yudong Quan; Christos J Petropoulos; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

5.  Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase.

Authors:  Hong-Tao Xu; Maureen Oliveira; Eugene L Asahchop; Matthew McCallum; Peter K Quashie; Yingshan Han; Yudong Quan; Mark A Wainberg
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

6.  Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir.

Authors:  Fenglei Huang; Kristin Drda; Thomas R MacGregor; Joseph Scherer; Lois Rowland; Thuy Nguyen; Charles Ballow; Mark Castles; Patrick Robinson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

7.  A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides.

Authors:  Yven Van Herrewege; Guido Vanham; Jo Michiels; Katrien Fransen; Luc Kestens; Koen Andries; Paul Janssen; Paul Lewi
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection.

Authors:  Joshua J Minuto; Richard Haubrich
Journal:  Futur HIV Ther       Date:  2008-11-01

9.  Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design.

Authors:  Valerie F Boltz; Frank Maldarelli; Neil Martinson; Lynn Morris; James A McIntyre; Glenda Gray; Mark J Hopley; Toshio Kimura; Douglas L Mayers; Patrick Robinson; John W Mellors; John M Coffin; Sarah E Palmer
Journal:  J Virol Methods       Date:  2009-12-03       Impact factor: 2.014

10.  Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies.

Authors:  Matthew S Lalonde; Ryan M Troyer; Aslam R Syed; Stanley Bulime; Korey Demers; Francis Bajunirwe; Eric J Arts
Journal:  J Clin Microbiol       Date:  2007-06-13       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.